LGBTQ+ adults face modestly elevated diabetes risk in many surveys, with the highest rates seen in bisexual women, transgender adults, and people living with HIV. Drivers include minority stress, healthcare avoidance, insurance gaps, depression, and higher obesity prevalence in some sub-groups. Gender-affirming hormone therapy can interact with diabetes care but is not a contraindication to it. Affirming, well-coordinated care — combining primary care, endocrinology, mental health, and HIV care when relevant — reduces barriers and improves outcomes.
Health Disparities in the LGBTQ+ Population
- Bisexual women show higher rates of obesity and type 2 diabetes than heterosexual women in several large surveys
- Transgender adults face elevated cardiovascular and metabolic risk
- Gay men in some surveys show similar or slightly lower diabetes rates than peers
- LGBTQ+ youth experience higher rates of depression and disordered eating — both linked to long-term glycemic risk
- Up to 1 in 5 LGBTQ+ adults report avoiding healthcare due to anticipated discrimination
Why LGBTQ+ Adults Face Higher Risk
| Driver | Detail |
|---|---|
| Minority stress | Chronic stigma, discrimination, and rejection raise cortisol and inflammatory markers |
| Healthcare avoidance | Anticipated discrimination delays screening and treatment |
| Insurance gaps | Coverage of gender-affirming care, partner benefits, and Medicaid coverage varies by state |
| Mental health | Higher rates of depression, anxiety, PTSD; bidirectional with diabetes risk |
| Smoking and alcohol | Higher prevalence in some LGBTQ+ subgroups |
| Disordered eating | Higher rates among gay men (body image) and transgender adults (dysphoria-related restriction or binge patterns) |
| HIV | Higher prevalence in some sub-groups; HIV and some ART regimens raise diabetes risk |
| Provider discomfort | Many providers report limited training in LGBTQ+ health |
Gender-Affirming Hormone Therapy and Diabetes
| Therapy | Metabolic Effects | Diabetes-Specific Notes |
|---|---|---|
| Feminizing estrogen (estradiol, anti-androgens) | Modest improvement in insulin sensitivity; increased VTE risk; possible breast tissue change | Transdermal estradiol preferred for lower VTE risk; lipid and glucose monitoring twice yearly |
| Masculinizing testosterone | Increased hematocrit; modest changes in glucose tolerance; possible visceral fat redistribution | Monitor A1C, hematocrit, lipids; consider waist circumference |
| GnRH agonists (puberty blockers) | Small short-term effects on bone density and body composition; reversible | Used in adolescents under specialist care; baseline and follow-up labs |
| Progesterone (adjunct) | Variable metabolic data; possible mood effects | Not routinely required; case by case |
Hormone regimens should be coordinated with diabetes care — both the endocrinologist managing diabetes and the gender medicine provider benefit from shared lab access and a unified treatment plan.
Transgender-Specific Diabetes Considerations
- BMI may underestimate or overestimate risk after body composition shifts on hormone therapy — waist circumference is more useful
- Glycated hemoglobin (A1C) is unaffected by hormone therapy directly
- Insulin pump and CGM placement options expand on the chest, abdomen, thighs, arms; discuss preferred body areas with the diabetes team
- Surgery (top/bottom) requires perioperative diabetes planning
- Mental health support before, during, and after transition supports diabetes self-care
HIV and Diabetes Overlap
- Chronic HIV infection raises type 2 diabetes risk through inflammation
- Older protease inhibitors and tenofovir alafenamide carry weight-gain and metabolic risk
- Integrase inhibitors (bictegravir, dolutegravir) are linked to weight gain
- Routine A1C and fasting lipid screening is part of comprehensive HIV care
- People with HIV and diabetes need coordinated care between HIV and endocrinology providers
Insurance and Legal Considerations
- Section 1557 of the Affordable Care Act prohibits sex-based discrimination including gender identity (subject to ongoing legal interpretation)
- Marketplace plans cover gender-affirming care variably by state and insurer
- Medicare and many Medicaid plans cover gender-affirming hormone therapy
- Same-sex spouse coverage applies under federal law since 2015
- Lambda Legal’s “Know Your Rights” resources help navigate denials
- Diabetes medications (GLP-1 agonists, CGM, pumps) follow standard coverage but pre-authorization can be a barrier
Finding Affirming Care
| Resource | What It Offers |
|---|---|
| GLMA Provider Directory (glma.org) | Searchable directory of LGBTQ+ affirming providers |
| Lambda Legal | Legal advocacy for healthcare access and insurance |
| HRC Healthcare Equality Index | Ratings of hospitals and health systems on LGBTQ+ inclusion |
| WPATH | Standards of care for transgender health |
| National LGBTQIA+ Health Education Center | Clinician training and patient resources |
| Trans Lifeline, The Trevor Project | Crisis support |
Diabetes Prevention Strategies
- Screen for diabetes per ADA standards (age 35, or earlier with risk factors); see our A1C levels guide
- Participate in DPP (Diabetes Prevention Program) — culturally affirming programs exist in many cities
- Address mental health alongside metabolic health
- Build a support network — LGBTQ+ diabetes communities exist online (Beyond Type 1, JDRF, T1 International forums)
- Smoking cessation
- Regular movement and a sustainable eating pattern — see diet and nutrition
- Annual labs including A1C, lipids, blood pressure, and (when relevant) HIV-related panels
Pediatric and Adolescent Care
- LGBTQ+ youth face higher rates of depression, anxiety, and disordered eating
- Routine pediatric diabetes screening uses standard criteria; family history and BMI still drive risk
- Gender-affirming pediatric care should be delivered by trained adolescent medicine, endocrinology, or gender medicine specialists
- Family acceptance is one of the strongest protective factors for LGBTQ+ youth mental and physical health
Related Reading
For other population-specific guides in this batch, see Native American diabetes and Asian American diabetes. For the foundation of risk understanding, start with our prediabetes 101 hub.
The Bottom Line
LGBTQ+ adults face modestly elevated type 2 diabetes risk overall, with the highest rates among bisexual women, transgender adults, and people with HIV. Causes include minority stress, healthcare avoidance, insurance gaps, mental health disparities, and higher obesity in some subgroups. Gender-affirming hormone therapy can be safely combined with diabetes prevention and treatment when monitored by knowledgeable providers. Affirming care — from intake forms to provider training — closes the access gap. LGBTQ+ patients deserve the same evidence-based diabetes screening, prevention, and treatment as everyone else, delivered in spaces where their identity is respected and integrated into care.
